All In Biotech

Drug Trial Radar · NCT02707861

Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1

A Phase 3, Multicenter, Expanded Access Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant (MDR) HIV-1

Last checked: Nov 20, 2026Latest source record: Mar 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

79

Actual

Start

Mar 2016

Primary completion

Nov 2018

Study completion Nov 2018

Sponsor

Lead sponsor
TaiMed Biologics Inc.Industry
Sponsor type
Industry
Collaborators
Westat
First posted
Mar 14, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Ibalizumab is a monoclonal antibody that works by blocking HIV entry into the immune system cells (CD4+ or T-cells) the virus typically infects. Ibalizumab is intended for use in combination with other anti-HIV drugs in people with multi-drug resistant HIV and limited treatment options. This study will collect further information on the safety and tolerability of intravenously administered (IV) ibalizumab combined with an optimized background regimen for treating multi-drug resistant HIV-1 infection, and will provide continuing access to ibalizumab for patients completing a prior ibalizumab clinical trial.

Conditions

  • HIV

Interventions

  • ibalizumabDrug

    Intravenous infusion of humanized monoclonal antibody binding with a region of Domain 2 of CD4 receptor, blocking post-attachment conformational changes necessary for HIV cell entry

  • Optimized Background RegimenDrug

    An investigator-selected, standard-of-care combination regimen of antiretroviral agents for treating HIV-1 infection, selected based upon patient treatment history and the results of previous viral resistance testing. The combination must contain at least one agent other than ibalizumab to which the patient's virus is sensitive (susceptible).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability of Ibalizumab + OBRTime frame: Through 48 weeks
  2. Discontinuations Due to Adverse Events Related to IbalizumabTime frame: 48 weeks
  3. Effectiveness of Ibalizumab + OBR (Cohort 2 Only)Time frame: 7 days

Locations

32 sites in 2 countries. Site status is shown where the registry gives one.

  • Long Beach Education and Research Consultants

    Long Beach, California

  • Southern California Permanente Medical Group

    Los Angeles, California

  • Ruane Clinical Research Institute Inc.

    Los Angeles, California

  • Charles R. Drew University of Medicine and Science, Clinical and Translational Research Center

    Los Angeles, California

  • Anthony Mills MD Inc.

    Los Angeles, California

  • Palmtree Clinical Research, Inc.

    Palm Springs, California

  • eStudy Site

    San Francisco, California

  • Kaiser Foundation Research Institute

    San Francisco, California

  • Yale University

    New Haven, Connecticut

  • Georgetown University School of Medicine

    Washington D.C., District of Columbia

  • Gary Richmond, MD, PA

    Fort Lauderdale, Florida

  • AIDS Healthcare Foundation - Kinder Medical Group

    Miami, Florida

  • AIDS Healthcare Foundation - South Beach

    Miami, Florida

  • Orlando Immunology Center

    Orlando, Florida

  • Triple O Research Institute

    West Palm Beach, Florida

  • AIDS Research Consortium of Atlanta

    Atlanta, Georgia

  • University of Hawaii - John A. Burns School of Medicine

    Honolulu, Hawaii

  • Howard Brown Health Center

    Chicago, Illinois

  • National Institute of Allergy & Infectious Diseases

    Bethesda, Maryland

  • ID Research Institute

    Springfield, Massachusetts

  • Central West Clinical Research

    St Louis, Missouri

  • AIDS Healthcare Foundation - Manhattan Midtown HCC

    New York, New York

  • Chelsea Village Medical

    New York, New York

  • Jacobi Medical Center

    The Bronx, New York

  • East Carolina University

    Greenville, North Carolina

  • Philadelphia FIGHT

    Philadelphia, Pennsylvania

  • St. Jude's Children's Research Hospital

    Memphis, Tennessee

  • St. Hope Foundation Community Health Center

    Bellaire, Texas

  • North Texas Infectious Disease Consultants

    Dallas, Texas

  • Crofoot Research Center

    Houston, Texas

  • Research Access Network

    Houston, Texas

  • Clinical Research PR, Inc.

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.